Biora Therapeutics, Inc.

Greetings and welcome to the Vaiara Therapeutic Second Quarter 2023 Earning Calls. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Chuck Padala, Managing Director with Life Science Advisor.

Thank you. You may begin. Thank you, Operator.

Good afternoon and welcome to the Biore Therapeutics Second Quarter 2023 Corporate Update and Financial Results Conference Call. Joining me on the call are Adi Mahanty, Chief Executive Officer, and Eric Desparves, Chief Financial Officer. Before I turn the call over to Mr. Mahanty, I would like to remind you that today's call will include forward-looking statements within the meeting of the Federal Securities Law, including, but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we've filed or will file later today and our subsequent reports with the SEC. which are available on our website in the investor section. These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those expressed in the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, as well as risks related to our business, please see the company's periodic reports with the SEC. With that, I will now turn the call over to Adi Mahanty, CEO of Iora Therapeutics.